Efficacy and Safety Evaluation of Budesonide/Formoterol SPIROMAX® Inhalation Powder Versus SYMBICORT® TURBOHALER®
Status:
Completed
Trial end date:
2014-07-01
Target enrollment:
Participant gender:
Summary
The primary objective of the study is to establish whether budesonide/formoterol fumarate
dihydrate (BF) SPIROMAX 160/4.5 mcg is as effective as SYMBICORT TURBOHALER 200/6 mcg
administered twice daily in patients with persistent asthma.
Phase:
Phase 3
Details
Lead Sponsor:
Teva Branded Pharmaceutical Products R&D, Inc. Teva Pharmaceutical Industries
Treatments:
Budesonide Budesonide, Formoterol Fumarate Drug Combination Formoterol Fumarate